Dabigatran for Mitral Stenosis Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 370 participants.
Also called NCT04045093
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 370 participants
- Sponsor
- Registry
-
NCT04045093
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Hong Kong SAR China
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04045093. Randomized; no masking; primary purpose prevention. Start 2020-10-22 (actual); primary completion 2026-09-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dabigatran for Mitral Stenosis Atrial Fibrillation
- Acronym
- David-MS
- Condition
- Atrial Fibrillation
- Condition
- Mitral Stenosis
- Intervention (Drug)
- Dabigatran etexilate
- Intervention (Drug)
- Warfarin
- Lead sponsor
- The University of Hong Kong
Record details
- Record id
cardio:ct-nct04045093- Content hash
abf80748986e6a829f3d532e370a51f2a481b814b34fc7633658d8542d02f97a